- ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
May 11, 2026
ANI Pharmaceuticals ANIP delivered first-quarter 2026 adjusted EPS of $2.05, up nearly 21% year over year and well ahead of the Zacks Consensus Estimate of $1.28.
Quarterly revenues totaled $237.5 million, up 20.5% from the year-ago period. The metric also beat the Zacks Consensus Estimate of $205.4 million.
The quarter reflected solid execution across the portfolio, led by continued momentum for Purified Cortrophin Gel and contributions from a newly monetized intellectual property licensing arrangement.
ANIP's Revenue Mix Tilts Toward Rare Disease and Royalties
Rare Disease and Brands' total net revenues were $128.2 million, up 36% year over year, supported by contributions from both Cortrophin Gel and Iluvien. Within that bucket, Cortrophin Gel net revenues rose 42% to $75.1 million, while Iluvien sales increased 19.5% to $19.3 million.
The reported Cortrophin sales marginally missed the Zacks Consensus Estimate of about $76 million. Per management, the drug’s sales were impacted primarily by seasonality tied to insurance re-verifications, which took longer to clear early in the quarter due to higher patient volume at physicians’ offices and weather-related physician office closures in some regions.
ANIP's shares fell more than 2% on Friday, suggesting some investors focused on the slightly softer-than-expected Cortrophin print despite the broader earnings and revenue beat. Year to date, the stock has gained about 4% against the industry’s nearly 3% decline.Zacks Investment Research
Image Source: Zacks Investment Research
The company also reported $21.5 million in brand royalties and other revenues in the quarter, reflecting the up-front payment and early royalty income tied to its Harmony Biosciences HRMY licensing agreement. By contrast, Brands' revenues declined 51% year over year to $12.3 million as demand normalized for certain products.
In January, the company’s Novitium subsidiary entered into an agreement with Harmony Biosciences, under which ANIP out-licensed intellectual property related to pitolisant, marketed under the brand name Wakix. The agreement generated a $15 million upfront license fee and includes low single-digit royalties on sales of pitolisant-based products. It provides for an additional $10 million in development milestones that management expects to be achieved in the second and third quarters of 2026.
ANIP Generics Business Adds Steady Growth
Generics and Other net revenues were $109.2 million in the first quarter, up 6% year over year. Growth was driven primarily by Generic pharmaceutical products, which rose about 7% to $105.4 million, supported by contributions from new launches and continued strength from the partnered generic launch that began in the third quarter of 2025.
Story Continues
Management said ANIP launched six new generics products year to date and remains on track to deliver 10-15 new generics launches in 2026.
ANIP Details Cortrophin Demand and Gout Commercial Expansion
As the re-verification backlog cleared, the company said momentum improved in February and March and carried into April, which posted the highest new patient starts and monthly volumes dispensed since launch. The company pointed to broad-based prescribing gains across targeted specialties, including rheumatology, nephrology, neurology, pulmonology and ophthalmology.
A key 2026 growth initiative is the planned expansion into acute gouty arthritis flares via a new dedicated commercial organization. ANIP expects the majority of this team to be in the field by the end of the second quarter, targeting about 7,000 high-priority primary care and podiatry prescribers and an estimated addressable population of roughly 285,000 patients; acute gouty arthritis flares represented about 18% of total Cortrophin utilization to date.
ANIP's Profitability Reflects Royalty-Bearing Mix Pressures
On a non-GAAP basis, cost of sales increased 28% year over year to $93.1 million, tracking higher volumes and a richer mix of royalty-bearing products. Adjusted gross margin was 60.8%, down about 230 basis points from the prior-year period.
ANIP attributed the margin contraction primarily to higher sales of royalty-bearing products, including Cortrophin Gel and a partnered generic product launched in the third quarter of 2025, as well as the non-recurrence of prior-year Prucalopride revenues. Management noted that these headwinds were partly offset by initial revenues recognized under the HRMY agreement.
ANIP's Spending Ramps With Rare Disease Investments
Adjusted selling, general and administrative expenses rose 12% year over year to $71.4 million, reflecting initial marketing and recruitment spending tied to the acute gout commercial buildout and broader activity to support growth. Adjusted research and development expense remained essentially flat year over year at about $10 million.
Despite the higher operating expense run rate, adjusted EBITDA increased 24% to $63 million, supported by the revenue lift and resulting gross profit growth.
ANIP Raises 2026 Guidance & Authorizes Share Repurchases
Following the strong start to the year, the company raised its full-year 2026 outlook for total net revenues by $25 million to $1.08-$1.14 billion and lifted adjusted EBITDA guidance by $10 million to $285-$300 million. Adjusted EPS is now expected in the range of $9.19-$9.69 (previously: $8.83-$9.34), while Cortrophin Gel net revenue guidance of $540-$575 million and Iluvien guidance of $78-$83 million were reaffirmed.
On the earnings call, the company tied its higher full-year outlook partly to stronger-than-expected Generics performance exiting the first quarter and improved visibility into upcoming launches for the remainder of the year.
Separately, ANIP’s board authorized a new $100 million share repurchase program running through May 2029, adding flexibility alongside its stated focus on business development.
ANIP's Cash Position Improves as Leverage Remains Manageable
The company ended the quarter with $311.2 million in unrestricted cash and cash equivalents, up from $285.6 million at the end of 2025. Operating cash flow was $58.4 million in the first quarter, reflecting the stronger earnings profile and working-capital dynamics.
As of March 31, 2026, the company reported $625 million in principal value of outstanding debt, inclusive of senior convertible notes and a term loan. Management cited gross leverage of 2.6x and net leverage of 1.3x based on trailing 12-month adjusted non-GAAP EBITDA of $242 million, positioning the balance sheet to support continued investment and potential inorganic opportunities.
ANIP’s Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold).
ANI Pharmaceuticals, Inc. PriceANI Pharmaceuticals, Inc. Price
ANI Pharmaceuticals, Inc. price | ANI Pharmaceuticals, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Amarin Corporation AMRN and Indivior Pharmaceuticals INDV, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $7.01 to $6.36. Over the same period, loss per share estimates for 2027 have improved from $5.50 to $4.64. AMRN's shares have risen 8% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters but missed the mark on one occasion, delivering an average surprise of 50.02%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 EPS have increased from $3.03 to $3.35. Over the same period, EPS estimates for 2027 have risen to $3.69 from $3.46. INDV's shares have risen 10% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 65.44%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report
Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Zacks.com featured highlights include ANI, Cummins and Seadrill
May 11, 2026
For Immediate Release
Chicago, IL – May 11, 2026 – Stocks in this week’s article are ANI Pharmaceuticals, Inc. ANIP, Cummins Inc. CMI and Seadrill Ltd. SDRL.
3 Stocks Showing Powerful Earnings Acceleration This May
As May began, astute investors started looking for companies demonstrating steady earnings growth as a sign of solid profitability. However, earnings acceleration is even more impactful and often serves as a stronger catalyst for driving stock prices higher. Studies indicate that top-performing stocks typically exhibit earnings acceleration before their share prices rise.
To that end, ANI Pharmaceuticals, Inc., Cummins Inc. and Seadrill Ltd. are showing strong earnings acceleration this month.
Earnings Acceleration Simplified
Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if a company’s quarter-over-quarter earnings growth rate increases within a stipulated time frame, it can be called earnings acceleration.
In the case of earnings growth, you pay for something that is already reflected in the stock price. However, earnings acceleration helps identify stocks that haven’t yet caught investors' attention and, once secured, will invariably lead to a rally in share price. This is because earnings acceleration considers both the direction and magnitude of growth rates.
An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may drag prices down.
The above criteria narrowed the universe of around 7,735 stocks to only 13. Here are three of the 13 stocks:
ANI Pharmaceuticals
ANI Pharmaceuticals develops, manufactures and markets branded and generic drugs in the U.S. and global markets. ANIP’s expected earnings growth rate for the current year is 14.3%. Currently, the company has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cummins
Cummins provides global power solutions through five segments: Engine, Distribution, Components, Power Systems and Accelera. CMI’s expected earnings growth rate for the current year is 9.6%. Currently, the company has a Zacks Rank #1.
Seadrill Ltd.
Seadrill Limited provides offshore drilling services to the global oil and gas industry. SDRL’s expected earnings growth rate for the current year is 179.2%. Currently, the company has a Zacks Rank #3.
Story Continues
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2918424/3-stocks-showing-powerful-earnings-acceleration-this-may
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cummins Inc. (CMI) : Free Stock Analysis Report
Seadrill Limited (SDRL) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
May 11, 2026 · zacks.com
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
- Is ANI Pharmaceuticals (ANIP) Still Attractively Priced After Recent Pipeline Developments?
May 9, 2026
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.
If you are wondering whether ANI Pharmaceuticals at around US$83.91 is still reasonably priced or already stretched, the starting point is to understand how the current market price lines up against different measures of value. The stock has returned 5.6% over the last week, 5.6% over the past month, 7.0% year to date and 17.3% over the last year, so recent price action is important context for any assessment of upside or downside. Recent company updates around its product portfolio and pipeline have kept attention on ANI Pharmaceuticals, while broader sector news has continued to shape how investors think about risks and opportunities in specialty pharma. Together, these factors help explain why the stock's recent returns stand where they do and why sentiment can shift quickly. Right now, ANI Pharmaceuticals has a valuation score of 3 out of 6, which suggests that some checks point to the stock as undervalued and others do not. The next sections will compare different valuation methods and then finish with a more comprehensive way to judge what the current price really implies.
Find out why ANI Pharmaceuticals's 17.3% return over the last year is lagging behind its peers.
Approach 1: ANI Pharmaceuticals Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model projects the cash the company is expected to generate in the future and then discounts those projections back to a single value in today’s dollars. It is essentially asking what all future free cash flows are worth right now.
For ANI Pharmaceuticals, the latest twelve month Free Cash Flow is about $154.2 million. Using a 2 Stage Free Cash Flow to Equity model, analysts and model estimates project free cash flow out over the next decade, with figures such as $175.1 million in 2026 and $221.8 million in 2027, then extending using Simply Wall St’s extrapolations through to 2035.
When all those projected cash flows are discounted back and summed, the model arrives at an estimated intrinsic value of about $365.71 per share. Versus the recent share price around $83.91, this suggests an intrinsic discount of roughly 77.1%. This indicates that the stock is trading well below this DCF estimate.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests ANI Pharmaceuticals is undervalued by 77.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.ANIP Discounted Cash Flow as at May 2026
Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for ANI Pharmaceuticals.
Story Continues
Approach 2: ANI Pharmaceuticals Price vs Earnings (P/E)
For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. It links directly to what the business currently earns, which makes it a useful cross check against more complex cash flow models.
What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher growth and lower perceived risk usually support higher P/E multiples, while slower growth or higher risk tend to justify lower ones.
ANI Pharmaceuticals currently trades on a P/E of 27.19x. That sits above the Pharmaceuticals industry average of about 16.05x and also above the peer average of 12.80x. Simply Wall St’s Fair Ratio for ANI Pharmaceuticals is 18.40x, which is a proprietary estimate of what the P/E might be given factors like its earnings growth profile, industry, profit margin, market cap and company specific risks.
This Fair Ratio can be more useful than a simple peer or industry comparison because it adjusts for those company specific features rather than assuming all stocks should trade on the same multiple. Comparing the Fair Ratio of 18.40x with the actual P/E of 27.19x suggests the stock is trading above this blended benchmark.
Result: OVERVALUEDNasdaqGM:ANIP P/E Ratio as at May 2026
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.
Upgrade Your Decision Making: Choose your ANI Pharmaceuticals Narrative
Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, letting you turn your view of ANI Pharmaceuticals into a simple story that links your assumptions about future revenue, earnings and margins to a fair value, then compares that fair value to today’s price so you can judge whether you see the stock as attractive or not.
On Simply Wall St’s Community page, Narratives are an easy tool used by millions of investors. You can see and build scenarios that connect the company’s story to a financial forecast, then instantly see what that implies for value.
Because Narratives update automatically when new information is added, such as earnings, guidance or product news, your fair value view can adjust without you rebuilding a model from scratch.
For ANI Pharmaceuticals, one investor might align with a more cautious Narrative that ties to a fair value around US$90.00 per share. Another might lean toward a more optimistic Narrative closer to US$120.00. Comparing each of these fair values with the current market price helps you decide which story you think is more realistic and what that means for your own next move.
Do you think there's more to the story for ANI Pharmaceuticals? Head over to our Community to see what others are saying!NasdaqGM:ANIP 1-Year Stock Price Chart
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ANIP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- ANI Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
May 9, 2026
This article first appeared on GuruFocus.
Release Date: May 08, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported a 20% year-over-year increase in total net revenues for the first quarter, driven by strong performance in both rare disease and generics businesses. The company raised its 2026 financial guidance for total revenue to a range of $1.08 billion to $1.14 billion and adjusted EBITDA to a range of $285 million to $300 million. Clotrophin Gel, a lead rare disease asset, saw a 42% year-over-year increase in net revenues, with strong momentum in new patient starts and monthly volumes dispensed. ANI Pharmaceuticals Inc (NASDAQ:ANIP) entered into a licensing transaction with Harmony Biosciences, receiving a $15 million upfront license fee and potential for additional milestone payments and royalties. The company launched six new generics products year-to-date and maintained its position as the number two player in overall CGT approvals.
Negative Points
Non-GAAP gross margin decreased by approximately 230 basis points from the prior-year period, primarily due to higher sales of royalty-bearing products. Insurance re-verifications took longer to clear in the first quarter, impacting Cortrophin Gel's performance due to seasonality and weather-related physician office closures. Non-GAAP selling, general, and administrative expenses increased by 12% due to initial marketing and recruitment expenses for organizational expansion. The company faces ongoing Medicare market access challenges for its retina franchise, impacting Alluvian sales. Despite strong first-quarter results, the company anticipates only modest sequential growth for Alluvian throughout the year.
Q & A Highlights
Warning! GuruFocus has detected 6 Warning Signs with MGLUY. Is ANIP fairly valued? Test your thesis with our free DCF calculator.
Q: Can you discuss the growth sources for Cortrophin, particularly in non-gout settings like pulmonology and ophthalmology, and the dynamics of vials and treatment duration across various indications? Also, how might payer access evolve as your footprint grows, especially in gout? A: The growth is primarily from core indications such as rheumatology, nephrology, neurology, pulmonology, and ophthalmology. The gout expansion will have a more significant impact in 2027. Vials and treatment duration vary by specialty, with pulmonology and nephrology requiring more vials per patient. Payer access is expanding as we bring competition to the ACTH category, focusing on reaching under-penetrated markets.
Story Continues
Q: Regarding the guidance increase and the Harmony deal, is the $10 million in development milestones included in your guidance? How are royalties factored in, and why isn't EBITDA guidance increasing more significantly? A: The guidance includes the Harmony deal, with the $10 million milestones expected in Q2 and Q3. The guidance increase is driven by higher generics revenues and clarity on milestone achievements. Royalties are refined based on updated guidance from Harmony. The EBITDA guidance reflects these factors and retains flexibility for further investments.
Q: On the Q2 guidance for Cortrophin, what are the drivers and visibility for achieving the projected numbers? How does the expansion into gout contribute to the second-half revenue? A: We exited Q1 with strong momentum, and April saw the highest new patient starts and volumes. The third and fourth quarters will benefit from the full deployment of our commercial organization and continued performance in core areas. The gout expansion targets 285,000 patients, with significant potential as we reach new prescribers.
Q: Can you clarify if the milestone payments from the Harmony deal were included in the original guidance, and what factors are influencing the raised guidance? A: The initial guidance included the Harmony deal, but the timing of milestone achievements was refined in the revised guidance. The raised guidance reflects higher generics revenues, clarity on milestone achievements, and flexibility for further investments in rare diseases and generics.
Q: Regarding Alluvian, why does the guidance suggest no sequential growth throughout the year, and what are the commercial and patient access initiatives in place? A: We have deployed commercial and patient access initiatives, but foundation-related access issues persist. We are exploring alternative access pathways and have upcoming clinical data releases that may impact future performance. The guidance is calibrated based on current conditions and expected developments.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
View Comments
- ANI Pharmaceuticals, Inc. (ANIP): A Small Cap Value Stock Capitalizing on Generic Drugs Opportunities
May 8, 2026
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is one of the best small-cap value stocks to buy. On April 20, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) confirmed the Food and Drug Administration’s approval of Pimozide Tablets in 1 mg and 2 mg strengths.ANI Pharmaceuticals, Inc. (ANIP): A Small Cap Value Stock Capitalizing on Generic Drugs Opportunities
Following approval, the company has launched Pimozide tablets, a generic version of the reference listed drug (RLD) Orap. The company has also successfully secured 180-day CGT exclusivity for the drug.
The launch underscores Ani Pharmaceuticals’ focus on bringing to market products with limited competition while offering generic alternatives to customers. Pimozide annual sales in the US total about $3.1 million
The launch of Pimozide tablets comes against the backdrop of the company’s launch of Carbamazepine Extended-Release Capsules in 100 mg, 200 mg, and 300 mg strengths. The launch of the generic version of RLD Carbatrol continues to strengthen the company’s generic portfolio. U.S. annual sales for Carbamazepine Extended-Release Capsules total approximately $65 million.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company that develops, manufactures, and commercializes high-quality branded, generic, and over-the-counter pharmaceuticals. They focus on rare diseases (ophthalmology, oncology) and maintain U.S.-based manufacturing facilities, including specialized capabilities for potent, high-containment products.
While we acknowledge the potential of ANIP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Oversold Canadian Stocks to Invest In and 10 Best Stocks to Buy in 2026 According to Billionaire George Soros.
Disclosure: None. Follow Insider Monkey on Google News.
View Comments
- 3 Stocks Showing Powerful Earnings Acceleration This May
May 8, 2026
As May began, astute investors started looking for companies demonstrating steady earnings growth as a sign of solid profitability. However, earnings acceleration is even more impactful and often serves as a stronger catalyst for driving stock prices higher. Studies indicate that top-performing stocks typically exhibit earnings acceleration before their share prices rise.
To that end, ANI Pharmaceuticals, Inc. ANIP, Cummins Inc. CMI and Seadrill Limited SDRL are showing strong earnings acceleration this month.
Earnings Acceleration Simplified
Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if a company’s quarter-over-quarter earnings growth rate increases within a stipulated time frame, it can be called earnings acceleration.
In the case of earnings growth, you pay for something that is already reflected in the stock price. However, earnings acceleration helps identify stocks that haven’t yet caught investors' attention and, once secured, will invariably lead to a rally in share price. This is because earnings acceleration considers both the direction and magnitude of growth rates.
An increasing percentage of earnings growth means that the company is fundamentally sound and has been on the right track for a considerable period. Meanwhile, a sideways percentage of earnings growth indicates a period of consolidation or slowdown, while a decelerating percentage of earnings growth may drag prices down.
Research Wizard Screening Parameters
Look at stocks for which the last two quarter-over-quarter percentage EPS growth rates exceed the previous periods’ growth rates. The projected EPS growth rate for the upcoming quarter is expected to exceed that of prior periods.
EPS % Projected Growth (Q1)/(Q0) greater than EPS % Growth (Q0)/(Q-1): The projected growth rate for the current quarter (Q1) over the completed quarter (Q0) has to be greater than the growth rate from the completed quarter (Q0) over one quarter ago (Q-1).
EPS % Growth (Q0)/(Q-1) greater than EPS % Growth (Q-1)/(Q-2): The growth rate for the completed quarter (Q0) over one quarter ago (Q-1) has to be greater than the growth rate from one quarter ago (Q-1) over two quarters ago (Q-2).
EPS % Growth (Q-1)/(Q-2) greater than EPS % Growth (Q-2)/(Q-3): The growth rate from one quarter ago (Q-1) over two quarters ago (Q-2) has to be greater than the growth rate from two quarters ago (Q-2) over three quarters ago (Q-3).
In addition to this, we have added the following parameters:
Current Price greater than or equal to $5: This screens out low-priced stocks.
Story Continues
Average 20-day volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.
The above criteria narrowed the universe of around 7,735 stocks to only 13. Here are three of the 13 stocks:
ANI Pharmaceuticals
ANI Pharmaceuticals develops, manufactures and markets branded and generic drugs in the U.S. and global markets. ANIP’s expected earnings growth rate for the current year is 14.3%. Currently, the company has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cummins
Cummins provides global power solutions through five segments: Engine, Distribution, Components, Power Systems and Accelera. CMI’s expected earnings growth rate for the current year is 9.6%. Currently, the company has a Zacks Rank #1.
Seadrill Limited
Seadrill Limited provides offshore drilling services to the global oil and gas industry. SDRL’s expected earnings growth rate for the current year is 179.2%. Currently, the company has a Zacks Rank #3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cummins Inc. (CMI) : Free Stock Analysis Report
Seadrill Limited (SDRL) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- ANI Pharmaceuticals Q1 Earnings Call Highlights
May 8, 2026 · marketbeat.com
ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.
- ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
May 8, 2026
For the quarter ended March 2026, ANI Pharmaceuticals (ANIP) reported revenue of $237.46 million, up 20.5% over the same period last year. EPS came in at $2.05, compared to $1.70 in the year-ago quarter.
The reported revenue represents a surprise of +15.61% over the Zacks Consensus Estimate of $205.41 million. With the consensus EPS estimate being $1.28, the EPS surprise was +60.16%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Revenues- Rare Disease and Brands- Cortrophin Gel: $75.12 million versus the four-analyst average estimate of $75.9 million. The reported number represents a year-over-year change of +42.1%. Total Net Revenues- Rare Disease: $94.37 million versus the four-analyst average estimate of $93.56 million. Net Revenues- Rare Disease and Brands- ILUVIEN and YUTIQ: $19.26 million versus the four-analyst average estimate of $17.66 million. The reported number represents a year-over-year change of +19.5%. Net Revenues- Generic pharmaceutical products: $105.4 million versus the three-analyst average estimate of $94.56 million. The reported number represents a year-over-year change of +6.8%.
View all Key Company Metrics for ANI here>>>
Shares of ANI have returned +4.7% over the past month versus the Zacks S&P 500 composite's +11% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
May 8, 2026 · seekingalpha.com
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
